# Immatics N.V. (IMTX)

> Source: Nexqual · https://nexqual.com/IMTX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Immatics N.V. (IMTX), nexqual.com/IMTX" · informational, not investment advice.

**Price:** USD 7.14 (+2.00% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 7 · day 6.95–7.2 · 52w 6.73–12.41 · market cap $1.09B · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 17.26 (range 11.8–25).
- Total return with dividends: 1Y -30.0% vs S&P 500 +18.1%; 5Y -48.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-17, EPS estimate USD -0.5, revenue estimate $12.5M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 17.26 (low 11.8, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Stifel | Initiated | Buy | $15 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -30.0% | -48.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -30.1% | -12.4% |
| Volatility (annualized) | 57.9% | 57.6% |
| Max drawdown | -42.5% (Dec 2025→Oct 2026) | -75.6% (Oct 2021→Mar 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/IMTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt